ARTICLE
27 July 2021

Drug Distributors And Major Pharmaceutical Company Reach $26 Billion Global Settlement With States To End Opioid Litigation

CO
Cozen O'Connor

Contributor

Founded in 1970, Cozen O’Connor has more than 925 attorneys practicing internationally in 32 cities across North America and Europe. We are a full-service firm with award-winning practices in litigation, business law, and government relations, and our attorneys have experience operating in all sectors of the economy. Our diverse client list includes global Fortune 500 companies, middle-market firms poised for growth, ambitious startups, and high-profile individuals.

A bipartisan group of AGs reached a $26 billion global settlement with three major drug distributors and Johnson & Johnson ("J&J") (collectively "Companies")...
United States Food, Drugs, Healthcare, Life Sciences
Cozen O'Connor are most popular:
  • with readers working within the Insurance industries
  • A bipartisan group of AGs reached a $26 billion global settlement with three major drug distributors and Johnson & Johnson ("J&J") (collectively "Companies"), pending approval by the vast majority of states and municipalities, to release the Companies from all civil liability relating to the opioid crisis.
  • Under the terms of the agreement, negotiated by a team of lawyers that included Cozen O'Connor's JB Kelly, the three distributors collectively will pay up to $21 billion over 18 years and J&J will pay up to $5 billion over nine years, with the substantial majority of the funds to be spent on opioid treatment and prevention. In addition, the distributors will establish an independent clearinghouse to provide aggregated data and analytics about drug distribution nationwide and will use data-driven systems to detect suspicious opioid orders from customer pharmacies. J&J agreed to stop selling and promoting opioids, and to share clinical trial data under the Yale University Open Data Access Project.
  • States and municipalities have 30 days to review the deal and provide formal approval.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More